Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.69 |
| ▸ | ACE | P12821 | 5/20 | 0.55 |
| ▸ | MME | P08473 | 3/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27412431 | 1.00 | NAALAD2 (0.69) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL159464 | 1.00 | NAALAD2 (0.69) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL31064856 | 0.97 | NAALAD2 (0.66) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL29854515 | 0.96 | NAALAD2 (0.68) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL16486437 | 0.96 | NAALAD2 (0.68) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL29854480 | 0.96 | NAALAD2 (0.68) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL16486435 | 0.96 | NAALAD2 (0.68) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL29531430 | 0.94 | NAALAD2 (0.62) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL29349540 | 0.94 | NAALAD2 (0.68) | NAALAD2ACEMMENPY1RNPY2R | |
| SCHEMBL30717713 | 0.93 | NAALAD2 (0.60) | NAALAD2ACEMMENPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4686419-A1 | FOOD COMPOSITION, AND USES THEREOF | Salssa Enterprises S.L. (ES) | 2026-02-04 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| US-20250129123-A1 | BIOMIMETIC PEPTIDES AND THEIR USE IN BONE REGENERATION | SILK BIOMATERIALS S.R.L. (IT) | 2025-04-24 | — | — | US | claimed |
| CN-118883955-A | Alzheimer's disease biomarker and application thereof in early diagnosis | 南方医科大学珠江医院 | 2024-11-01 | — | — | CN | claimed |
| CN-118660707-A | Supermolecule self-assembly system | 北京睿创康泰医药研究院有限公司 | 2024-09-17 | — | — | CN | claimed |
| WO-2024162422-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | ハウス食品グループ本社株式会社 | 2024-08-08 | — | — | WO | claimed |
| WO-2024162421-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | ハウス食品株式会社 | 2024-08-08 | — | — | WO | claimed |
| CN-116444605-A | Active peptide, active peptide composition and application thereof in preparation of anti-aging products | 深圳海创生物科技有限公司 | 2023-07-18 | — | — | CN | claimed |
| US-20150377910-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2015-12-31 | — | — | US | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| WO-2013188333-A1 | BIOMARKERS RELATED TO NEPHROTOXICITY AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-12-19 | — | — | WO | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |
| EP-0608217-A1 | SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608217-A4 | SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION. | RES CORP TECHNOLOGIES INC (US) | 1993-12-06 | — | — | EP | claimed |
| WO-1991016067-A1 | SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | NAALAD2 4066/4885ACE 573/4885MME 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.